Clay Siegall is recorded as Board Member at Shattuck Labs, Inc. (STTK) and CEO at Immunome Inc. (IMNM). The newest filing on record that lists Clay Siegall as Board Member at Shattuck Labs, Inc. (STTK) is dated April 8, 2026. The newest filing on record that lists Clay Siegall as CEO at Immunome Inc. (IMNM) is dated April 24, 2026. Immunome Inc. reported in an 8-K filed October 4, 2023 that Clay Siegall was appointed Chief Executive Officer, President, Chairman of the Board and Class I Director, effective October 2, 2023. The proxy statement of Immunome Inc. reports total compensation of $14,866,831 for Clay Siegall in fiscal 2023, including a base salary of $162,500. Clay Siegall has spoken on 1 investor event across 1 company, most recently for Immunome Inc. on September 14, 2026. Immunome Inc. is classified in the Biotechnology industry within the Healthcare sector. Shattuck Labs, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Immunome Inc. includes Clay B. Siegall, Ph.D. (CEO), Corleen Roche (CFO), Diane Marcou (CFO) and 7 others.
“Immediately following the effective time of the Merger, Immunome's board of directors (and its committees) and executive officers were reconstituted to include the following directors and executive officers”
Immunome Inc. Form 8-K, filed October 4, 2023
· Read the filing
Clay Siegall on recent calls
“So the goal of Immunome is to make targeted therapies for cancer patients. I've made quite a few drugs that are on the market around the world in my career, and it's my passion to help cancer patients.”
